㊙️フランス厚生省 認知症治療薬を健康保険から外す‼️ | 『誤診だらけの認知症』☆☆☆一人では「商売」もできない外来医たち

『誤診だらけの認知症』☆☆☆一人では「商売」もできない外来医たち

Nobody is in possession of the ultimate truth.
真理追究 第三極自主独立戦略
偽装解除
殲滅モード『メギド』開始!!
もはや 知っていたとは言わせない


テーマ:
6月1日。

🇫🇷フランス🇫🇷

もう、
パリに行ったのは35年も昔笑い泣き

英語で尋ねたところ、
フランス語で返事をくれる
ポリスの“優しさ”
に震えたもの。

今度は、
“高等保健局”
とでも訳せばイイのでしょうか、
その決断に
感動して震えました。

要は、
認知症治療薬、
ドネペジル
(例えばアリセプト®︎)
ガランタミン
(レミニール®︎)、
リバスチグミン
(例えばリバスタッチ®︎)、
メマンチン
(メマリー®︎)
の4薬剤は
効果が低い割に、
重大な
消化器・循環器・神経精神系副作用
もあり、
保険医療下に
置く価値がない
とバッサリ一刀両断。

代わりに、
かかりつけ医の役割強化、
介護者のサポート、
Les Equipes Specialisees Alzheime(ESA)
と呼ばれる
特別チームの全国展開などに
ムダにならないで済んだカネを回す、
とまでは書いてないか笑い泣き


今さらながら
極めて当然の結果。


飲まないと認知症が進むぞ‼️

いやいや、
飲んでも悪化は、
理論上、
止まりません。


代わりに、
栄養
を取れば治りますよ‼️
なんて、
絶対に言いません。

また、
運動
すれば治りますよ‼️
もあり得ません。

中枢神経の変性は
不可逆的。

ムダなことに
貴重なオカネや時間を
費やさないことです。


認知症が治る❓


白内障と診断された
水晶体を非観血的に治せたり、
自分の髪の毛を増やせてから
言いましょう。




MCIまでが勝負。

自立喪失回避
健康寿命の延伸こそ、
我が使命。




社会保険・健康管理部の
プレスリリースより。



もちろん、仏語ですから英語に変換。


The therapeutic value 
of 
Alzheimer's drugs 
is not enough 
to justify 
their coverage 
by health insurance

アルツハイマー薬
の治療効果は
健康保険管理下に不適当


In France, the legitimacy of the reimbursement of medicines by health insurance is regularly reassessed by the High Authority of Health (HAS) to ensure that they have a significant therapeutic interest.

The Transparency Commission (CT), made up of independent experts from the High Authority for Health, has recently reassessed the actual benefit of drugs for Alzheimer's disease [1]. 


上差し

Based on all available medical and scientific data, she has shown that these drugs have a low efficacy, as well as digestive, cardiovascular and neuropsychiatric adverse effects that can be serious and require the definitive cessation of treatment (until at 30% stop in clinical studies).

The independent scientific evaluation 
of the High Authority of Health 
therefore concluded that 
the clinical interest of these products was insufficient to justify their care.

Care in the context of Alzheimer's disease is primarily based on appropriate multidisciplinary care. 

As such, the Haute Autorité de Santé has issued recommendations to ensure that the care path of all patients is personalized at each stage of their illness. 

Thanks to the coordinated action of health professionals, the goal is to maintain the greatest possible autonomy for patients. 

A guide and practical fact sheets to "set up a path of care and adapted support" for patients suffering from Alzheimer's and related diseases were published by the HAS on May 25th.

The Ministry of Solidarity and Health draws the consequences of these recommendations from the HAS by issuing a decree which provides that, 
as of August 1, 2018, 
the purchase of drugs 
for Alzheimer's disease 
will no longer 
be the subject of 
reimbursement 
by health insurance. 

This is a measure taken in the interest of the health of citizens and which will strengthen the coordinated care of patients concerned.

In fact, 
to improve the care of patients, the role of general practitioners in screening and accompanying patients has recently been strengthened. 

They have more opportunities to carry out long consultations in patients' homes, to take stock of the disease and ensure quality care. 

Caring for caregivers of sick people, whose role is essential on a daily basis, has also been strengthened, thanks to a continuous increase in the number of support and respite platforms that provide them with advice and support. 

Specialized Alzheimer's teams (ESA), which provide care for patients at key moments in their illness, are also developing throughout the country. 

All these measures are likely to strengthen the quality of care in all its dimensions.

For the future, the search for effective treatments to fight against Alzheimer's disease remains a major challenge. 

France is fully engaged in this work and devotes significant resources each year to research on neurodegenerative diseases and dementia.